Non-alcoholic Fatty Liver Disease: all 1,507 studies

Page 4 of 16. Open to participants first (303), then studies with results posted, then the rest; newest registration first within each.

• Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)Enrolling by invitationNCT00983463
• The Danish Childhood Obesity BiobankRecruitingNCT00928473Not applicable
• Prospective Cohort Study in Patients With NAFLDRecruitingNCT00575133
• The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical SettingCompletedNCT07021443Results posted
• Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)CompletedNCT06482112Phase 2Results posted
• A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)CompletedNCT06052566Phase 1Results posted
• A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT06007651Phase 1Results posted
• A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver DiseaseCompletedNCT05970640Phase 1Results posted
• Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 DiabetesCompletedNCT05844137Not applicableResults posted
• Conditionally Increased Output (CIO) Enhanced Ultrasound SystemCompletedNCT05792423Not applicableResults posted
• Glycemic Effect of Diazoxide in NAFLDCompletedNCT05729282Phase 1Results posted
• The Effects of Glucagon on Hepatic MetabolismCompletedNCT05500586Phase 1/2Results posted
• DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisCompletedNCT05415722Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedNCT05364931Phase 2Results posted
• The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseCompletedNCT05364684Phase 2Results posted
• Phase 2a Study of HPG1860 in Subjects With NASHCompletedNCT05338034Phase 2Results posted
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusCompletedNCT05232071Phase 2Results posted
• Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USTerminatedNCT05211284Phase 2Results posted
• A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)CompletedNCT05039450Phase 2Results posted
• The University of Michigan Wellness for Liver Health StudyCompletedNCT05010070Phase 1/2Results posted
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT04971785Phase 2Results posted
• A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)CompletedNCT04944992Phase 2Results posted
• Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04929483Phase 2Results posted
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04906421Phase 2Results posted
• AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic SteatohepatitisCompletedNCT04897594Phase 1Results posted
• Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI VolunteersCompletedNCT04874233Phase 2Results posted
• Study in Healthy Adults Evaluating PF-07202954CompletedNCT04857437Phase 1Results posted
• Noninvasive Biomarkers of Metabolic Liver Disease 1.1CompletedNCT04828551Not applicableResults posted
• Vitamin E Dosing StudyCompletedNCT04801849Phase 2Results posted
• Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot StudyCompletedNCT04800094Not applicableResults posted
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)CompletedNCT04771273Phase 2Results posted
• A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04767529Phase 2Results posted
• A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialCompletedNCT04685993Phase 2Results posted
• Study of Oral Idebenone to Treat Non-Alcoholic SteatohepatitisCompletedNCT04669158Phase 1/2Results posted
• Ultrasound-Based Liver Fat Quantification (LFQ) Pilot StudyCompletedNCT04657523Not applicableResults posted
• A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04618744Phase 2Results posted
• A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04616014Phase 2Results posted
• A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)TerminatedNCT04583423Phase 2Results posted
• Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver DiseaseTerminatedNCT04576923Not applicableResults posted
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD StudyActive, not recruitingNCT04550481Phase 2Results posted
• Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCompletedNCT04521114Phase 2Results posted
• A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 SubjectsCompletedNCT04480710Phase 2Results posted
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompletedNCT04399538Phase 2Results posted
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHTerminatedNCT04378010Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisTerminatedNCT04365868Phase 2/3Results posted
• Effects of High-Intensity Interval Training Exercise in Adolescents With HepatosteatosisCompletedNCT04342390Not applicableResults posted
• LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)CompletedNCT04328077Phase 2Results posted
• Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04321343Phase 2Results posted
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)CompletedNCT04321031Phase 2Results posted
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)TerminatedNCT04267393Phase 2Results posted
• Effect of Obesity on Proton Pump InhibitorsCompletedNCT04248335Phase 4Results posted
• Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder MessagesCompletedNCT04241575Not applicableResults posted
• A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT04237116Phase 3Results posted
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)CompletedNCT04210245Phase 2Results posted
• Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASHCompletedNCT04202354Phase 1/2Results posted
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)CompletedNCT04198805Phase 2Results posted
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and SteatohepatitisTerminatedNCT04175392Phase 1/2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic SteatohepatitisTerminatedNCT04171765Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04166773Phase 2Results posted
• Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)TerminatedNCT04147195Phase 2Results posted
• The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic SteatohepatitisCompletedNCT04134091Phase 2Results posted
• A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)SuspendedNCT04104321Phase 3Results posted
• Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT04073368Not applicableResults posted
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.TerminatedNCT04065841Phase 2Results posted
• A Phase 2b Study of Icosabutate in Fatty Liver DiseaseCompletedNCT04052516Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHCompletedNCT04048135Phase 1/2Results posted
• Aspirin for the Treatment of Nonalcoholic Fatty Liver DiseaseCompletedNCT04031729Phase 1/2Results posted
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedNCT04019561Phase 2Results posted
• A Phase 2 Study of Elobixibat in Adults With NAFLD or NASHCompletedNCT04006145Phase 2Results posted
• Alternate Day Fasting, Exercise, and NAFLDCompletedNCT04004403Not applicableResults posted
• A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic SteatohepatitisTerminatedNCT04004325Phase 1/2Results posted
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageCompletedNCT03987451Phase 2Results posted
• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT03987074Phase 2Results posted
• A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT03976401Phase 2Results posted
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes MellitusCompletedNCT03969719Phase 2Results posted
• Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03938246Phase 2Results posted
• Treating PCOS With Semaglutide vs Active Lifestyle InterventionCompletedNCT03919929Phase 2/3Results posted
• Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)CompletedNCT03912532Phase 2Results posted
• Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)TerminatedNCT03883607Phase 2Results posted
• Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedNCT03863574Phase 2Results posted
• Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver DiseaseCompletedNCT03839082Not applicableResults posted
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03823703Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT03812029Phase 2Results posted
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.CompletedNCT03776175Phase 2Results posted
• A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLDCompletedNCT03763877Phase 2Results posted
• A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDCompletedNCT03744182Phase 1Results posted
• Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver DiseaseCompletedNCT03696797Not applicableResults posted
• Vitamin E for NASH Treatment in HIV Infected IndividualsTerminatedNCT03669133Phase 2Results posted
• A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)CompletedNCT03656744Phase 2Results posted
• An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With FibrosisCompletedNCT03656068Phase 2Results posted
• Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2Results posted
• Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)TerminatedNCT03617263Phase 2Results posted
• Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced TrialsCompletedNCT03611101Results posted
• Spironolactone Therapy In Young Women With NASHCompletedNCT03576755Phase 1/2Results posted
• A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03551522Phase 2Results posted
• Mild Hypothermia and Acute Kidney Injury in Liver TransplantationTerminatedNCT03534141Not applicableResults posted
• Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisCompletedNCT03517540Phase 2Results posted
• 2-Week Study In People With Nonalcoholic Fatty Liver DiseaseCompletedNCT03513588Phase 1Results posted

← Non-alcoholic Fatty Liver Disease overview